0.00
100.00%
-58.70
Mirati Therapeutics Inc 주식(MRTX)의 최신 뉴스
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion - MSN
MSN
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing - MSN
MSN
Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago - Yahoo Canada Shine On
Yahoo Canada Shine On
Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Even after rising 4.0% this past week, Mirati Therapeutics (NASDAQ:MRTX) shareholders are still down 76% over the ... - Yahoo Canada Shine On
Yahoo Canada Shine On
What You Need To Know About The Mirati Therapeutics, Inc. (NASDAQ:MRTX) Analyst Downgrade Today - Yahoo Movies UK
Yahoo Movies UK
Citi upgrades Mirati to buy; cites valuation, leadership change - MSN
MSN
TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board - Yahoo Canada Finance
Yahoo Canada Finance
Broader KRAS inhibition methods include chaperoning, gluing, vaccinating - BioWorld Online
BioWorld Online
Merck puts KRAS cancer drug competitor to the test - Yahoo Finance
Yahoo Finance
Bristol Myers Squibb to lay off hundreds of workers following its $4.8B merger with this San Diego biotech - The San Diego Union-Tribune
The San Diego Union-Tribune
Bristol Myers says KRAS drug succeeds in key trial - Yahoo Finance
Yahoo Finance
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and ... - Business Wire
Business Wire
Bristol Myers Squibb's Abecma recommended for EU approval - Pharmaceutical Technology
Pharmaceutical Technology
Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges - Bloomberg
Bloomberg
Tango Therapeutics: Making Its Way Into Clinic With 4 Cancer Drugs (NASDAQ:TNGX) - Seeking Alpha
Seeking Alpha
Bristol Myers Squibb concludes Mirati acquisition for $5.8bn - Pharmaceutical Technology
Pharmaceutical Technology
Bristol Myers Squibb completes acquisition of Mirati Therapeutics, strengthening oncology portfolio - ROI-NJ.com
ROI-NJ.com
2023's top 10 clinical trial flops - Fierce Biotech
Fierce Biotech
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers - Seeking Alpha
Seeking Alpha
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Zacks Investment Research
European Commission Approves Adagrasib in KRAS G12C-Mutated NSCLC - Cancer Network
Cancer Network
Jan. 10 Quick Takes: Coherus ends TIGIT deal with Junshi - BioCentury
BioCentury
HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the ... - GlobeNewswire
GlobeNewswire
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
Zacks Investment Research
Mirati Therapeutics describes new GTPase KRAS and mutant inhibitors for cancer - BioWorld Online
BioWorld Online
Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Seeking Alpha
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
Zacks Investment Research
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Zacks Investment Research
Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push - CNBC
CNBC
Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX) - Seeking Alpha
Seeking Alpha
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
Zacks Investment Research
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B - Yahoo Finance
Yahoo Finance
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024 - Yahoo Finance
Yahoo Finance
EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Analyst Expectations For Mirati Therapeutics's Future
Benzinga
Sanofi licenses fourth NK cell engager from Innate Pharma - Pharmaceutical Technology
Pharmaceutical Technology
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Zacks Investment Research
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
Zacks Investment Research
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug - Yahoo Finance
Yahoo Finance
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
Zacks Investment Research
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight - PR Newswire
PR Newswire
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Zacks Investment Research
MRTX-1257 enhances radiotherapy effect in preclinical setting - BioWorld Online
BioWorld Online
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire
PR Newswire
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations - Yahoo Finance
Yahoo Finance
Mirati wins conditional UK approval for Krazati in NSCLC - Pharmaceutical Technology
Pharmaceutical Technology
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire
PR Newswire
자본화:
|
볼륨(24시간):